EFCCA Magazine 2/2023
Our latest issue of the EFCCA magazine is out!!!
You will find updates on our activities, news from our members and partners, experiences of living with IBD and ongoing medical research.
Happy reading!
Empowerment
EFCCA Magazine 2/2023
DIVA - Data Insights for added therapeutic VAlue
EFCCA´s new working methodology aims to identify and address the real needs of patients with Crohn’s disease and Ulcerative Colitis, also collectively known as Inflammatory Bowel Disease (IBD).
The working methodology is based on the concept of analysing and interpreting scientific data in order to improve therapeutic outcomes. EFCCA’s approach is called DIVA (Data Insights for Added therapeutic VAlue) which will make use of publicly available data as well as internal EFCCA data to analyse and interpret the IBD patient communities’ unmet needs.
Horizon Europe - FIBROTARGET
EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD.
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence
November, 2022
The study developed a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Other indicators include, for example, clinical, endoscopic, and biomarker remission, fatigue, and urgency to go to the toilet.
Horizon Europe - miGut
We take great pleasure in informing you that EFCCA is one of the 12 partners coming from 9 countries of the consortium for the miGut-Health Project, which has been selected for European funding under the Horizon 2020 framework. This project will strive to empower people living with IBD by creating state-of-the-art strategies for early disease prediction, prevention, and health monitoring. This will be achieved through data-driven approaches, personalised preventive interventions (such as nutritional changes), and innovative eHealth solutions.
Horizon Europe - METHYLOMIC
The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated.
Horizon Europe - GlycanTrigger
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention.
Horizon Europe - GENEGUT
The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.
Horizon 2020 - ImmUniverse
EFCCA is involved in an exciting EU Research Project under the Innovative Medicines Initiative (IMI 2) (Horizon 2020).
The ImmUinverse project main goal is the improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis. New insights into disease severity and progression will enable personalised therapy for each individual patient.